CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CyTuVax B.V. focuses on developing a novel cancer vaccine, PanCaVax, using a patented technology that enhances immune responses. The project aims to improve survival rates for pancreatic cancer patients by utilizing a unique adjuvant approach that minimizes side effects and costs compared to existing treatments.
CyTuVax B.V. is a biotech enterprise founded in Maastricht (the Netherlands) in October 2012.
It applies depot-formulatedcytokines (interaction molecules of the immune system), which enhance immune responses in an unprecedented mannerwhen used in extremely high local density.
Single and multi-cytokine combinations can be formulated by simple proceduresand act as strong adjuvants, driving immune responses to their limits.
It is a universal, patented platform adjuvant technologythat can be applied…
CYTUVAX BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
